Methocarbamol

Generic Name: Methocarbamol
Brand Name: RELAXIMOL ®
Dosage Form: Injection 1G/10ml
Pharmacological Category: Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.
Therapeutic Category: Antimyasthenics, Muscle Relaxant
Pregnancy Category: C

Pharmacology

The mechanism of action of Methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics:

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

Indications:

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Contraindications:

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

Precautions:

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug Interactions:

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

Side Effects:

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

Storage:

• Store below 30 C°
• Protect from light and freezing

Packing:

• Injection 1G/10ml: 5 Ampoules/box

stdClass Object ( [nid] => 278 [type] => product [language] => en [uid] => 1 [status] => 1 [created] => 1373631587 [changed] => 1388741276 [comment] => 0 [promote] => 0 [moderate] => 0 [sticky] => 0 [tnid] => 105 [translate] => 0 [vid] => 278 [revision_uid] => 1 [title] => Methocarbamol [body] =>
Image: 
Brand Name: 

RELAXIMOL ®

Dosage Form: 

Injection 1G/10ml

Pharmacological Category: 

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

Therapeutic Category: 

Antimyasthenics, Muscle Relaxant

Pregnancy Category: 

C

The mechanism of action of Methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics: 

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

Indications: 

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Contraindications: 

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

Precautions: 

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug Interactions: 

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

Side Effects: 

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Injection 1G/10ml: 5 Ampoules/box

[log] => [revision_timestamp] => 1388741276 [format] => 1 [name] => root [picture] => [data] => a:5:{s:29:"taxonomy_image_disable_images";i:0;s:20:"l10n_client_disabled";i:0;s:13:"form_build_id";s:48:"form-MBxN_vyi5HhAsg0I2XKWS7o1OdWz8gzblI4ECSrLqIU";s:18:"admin_compact_mode";b:1;s:7:"contact";i:0;} [path] => product/methocarbamol [field_one_image] => Array ( [0] => Array ( [fid] => 172 [uid] => 1 [filename] => methocarbamol_s.jpg [filepath] => sites/default/files/images/methocarbamol_s.jpg [filemime] => image/jpeg [filesize] => 52928 [status] => 1 [timestamp] => 1329486286 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 278 [view] => ) ) [field_administration_and_dosage] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_brand_name] => Array ( [0] => Array ( [value] => RELAXIMOL ® [format] => 1 [safe] =>

RELAXIMOL ®

[view] =>

RELAXIMOL ®

) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components. [format] => 1 [safe] =>

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

[view] =>

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

) ) [field_dosage_form] => Array ( [0] => Array ( [value] => Injection 1G/10ml [format] => 1 [safe] =>

Injection 1G/10ml

[view] =>

Injection 1G/10ml

) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results. [format] => 1 [safe] =>

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

[view] =>

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

) ) [field_indications] => Array ( [0] => Array ( [value] => Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. [format] => 1 [safe] =>

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

[view] =>

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

) ) [field_packing] => Array ( [0] => Array ( [value] => • Injection 1G/10ml: 5 Ampoules/box [format] => 1 [safe] =>

• Injection 1G/10ml: 5 Ampoules/box

[view] =>

• Injection 1G/10ml: 5 Ampoules/box

) ) [field_pdf] => Array ( [0] => Array ( [fid] => 173 [uid] => 1 [filename] => methocarbamol.pdf [filepath] => sites/default/files/pdf/methocarbamol.pdf [filemime] => application/pdf [filesize] => 144121 [status] => 1 [timestamp] => 1329486392 [list] => 1 [data] => [i18nsync] => 1 [nid] => 278 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%. Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine. [format] => 1 [safe] =>

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

[view] =>

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. [format] => 1 [safe] =>

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

[view] =>

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

) ) [field_precautions] => Array ( [0] => Array ( [value] => • Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. • Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants. [format] => 1 [safe] =>

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

[view] =>

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => C [format] => 1 [safe] =>

C

[view] =>

C

) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => Cardiovascular: Cardiovascular side effects have included syncope, hypotension, and bradycardia. Nervous system: Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy. Dermatologic: Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site. Ocular: Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia. Respiratory: Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis. Gastrointestinal: Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus. Other: Other side effects have included metallic taste and fever. Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). Hematologic: Hematologic side effects have included hemolysis, particularly with intravenous injection. Renal: Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency. Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients. General: General side effects have included angioneurotic edema. [format] => 1 [safe] =>

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

[view] =>

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

) ) [field_storage] => Array ( [0] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[view] =>

• Store below 30 C°
• Protect from light and freezing

) ) [field_therapeutic_category] => Array ( [0] => Array ( [value] => Antimyasthenics, Muscle Relaxant [format] => 1 [safe] =>

Antimyasthenics, Muscle Relaxant

[view] =>

Antimyasthenics, Muscle Relaxant

) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [3] => stdClass Object ( [tid] => 3 [vid] => 1 [name] => Antimyasthenics ,Muscle Relaxants [description] => [weight] => 1 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 172 [uid] => 1 [filename] => methocarbamol_s.jpg [filepath] => sites/default/files/images/methocarbamol_s.jpg [filemime] => image/jpeg [filesize] => 52928 [status] => 1 [timestamp] => 1329486286 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 278 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
[#printed] => 1 ) [field_brand_name] => Array ( [#type_name] => product [#context] => full [#field_name] => field_brand_name [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_brand_name [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => RELAXIMOL ® [format] => 1 [safe] =>

RELAXIMOL ®

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

RELAXIMOL ®

) [#title] => [#description] => [#children] =>

RELAXIMOL ®

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

RELAXIMOL ®

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Brand Name: 

RELAXIMOL ®

[#printed] => 1 ) [field_dosage_form] => Array ( [#type_name] => product [#context] => full [#field_name] => field_dosage_form [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_dosage_form [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Injection 1G/10ml [format] => 1 [safe] =>

Injection 1G/10ml

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Injection 1G/10ml

) [#title] => [#description] => [#children] =>

Injection 1G/10ml

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Injection 1G/10ml

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Dosage Form: 

Injection 1G/10ml

[#printed] => 1 ) [#pre_render] => Array ( [0] => content_alter_extra_weights ) [field_pharmacological_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacological_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 0 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacological_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. [format] => 1 [safe] =>

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

) [#title] => [#description] => [#children] =>

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacological Category: 

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

[#printed] => 1 ) [#content_extra_fields] => Array ( [title] => Array ( [label] => Generic Name [description] => Node module form. [weight] => -5 ) [body_field] => Array ( [label] => Pharmacology [description] => Node module form. [weight] => 3 [view] => body ) [revision_information] => Array ( [label] => Revision information [description] => Node module form. [weight] => 18 ) [author] => Array ( [label] => Authoring information [description] => Node module form. [weight] => 19 ) [options] => Array ( [label] => Publishing options [description] => Node module form. [weight] => 20 ) [language] => Array ( [label] => Language [description] => Locale module form. [weight] => -4 ) [translation] => Array ( [label] => Translation settings [description] => Translation module form. [weight] => 21 ) [menu] => Array ( [label] => Menu settings [description] => Menu module form. [weight] => 17 ) [taxonomy] => Array ( [label] => Taxonomy [description] => Taxonomy module form. [weight] => -3 ) [path] => Array ( [label] => Path settings [description] => Path module form. [weight] => 16 ) [custom_breadcrumbs] => Array ( [label] => Custom Breadcrumbs [description] => Custom Breadcrumbs module form. [weight] => 30 ) ) [field_therapeutic_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_therapeutic_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_therapeutic_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Antimyasthenics, Muscle Relaxant [format] => 1 [safe] =>

Antimyasthenics, Muscle Relaxant

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Antimyasthenics, Muscle Relaxant

) [#title] => [#description] => [#children] =>

Antimyasthenics, Muscle Relaxant

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Antimyasthenics, Muscle Relaxant

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Therapeutic Category: 

Antimyasthenics, Muscle Relaxant

[#printed] => 1 ) [field_pregnancy_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pregnancy_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pregnancy_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => C [format] => 1 [safe] =>

C

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

C

) [#title] => [#description] => [#children] =>

C

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

C

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pregnancy Category: 

C

[#printed] => 1 ) [body] => Array ( [#weight] => 3 [#value] =>

The mechanism of action of Methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%. Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine. [format] => 1 [safe] =>

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

) [#title] => [#description] => [#children] =>

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacokinetics: 

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

[#printed] => 1 ) [field_indications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_indications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 5 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_indications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. [format] => 1 [safe] =>

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

) [#title] => [#description] => [#children] =>

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Indications: 

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

[#printed] => 1 ) [field_administration_and_dosage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_administration_and_dosage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 6 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_administration_and_dosage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_administration_and_dosage [#title] => Administration and Dosage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_contraindications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_contraindications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 7 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_contraindications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components. [format] => 1 [safe] =>

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

) [#title] => [#description] => [#children] =>

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Contraindications: 

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

[#printed] => 1 ) [field_precautions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_precautions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 8 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_precautions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. • Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants. [format] => 1 [safe] =>

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

) [#title] => [#description] => [#children] =>

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Precautions: 

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

[#printed] => 1 ) [field_drug_interactions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_drug_interactions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 9 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_drug_interactions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results. [format] => 1 [safe] =>

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

) [#title] => [#description] => [#children] =>

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_drug_interactions [#title] => Drug Interactions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Drug Interactions: 

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

[#printed] => 1 ) [field_side_effects] => Array ( [#type_name] => product [#context] => full [#field_name] => field_side_effects [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 10 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_side_effects [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Cardiovascular: Cardiovascular side effects have included syncope, hypotension, and bradycardia. Nervous system: Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy. Dermatologic: Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site. Ocular: Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia. Respiratory: Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis. Gastrointestinal: Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus. Other: Other side effects have included metallic taste and fever. Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). Hematologic: Hematologic side effects have included hemolysis, particularly with intravenous injection. Renal: Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency. Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients. General: General side effects have included angioneurotic edema. [format] => 1 [safe] =>

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

) [#title] => [#description] => [#children] =>

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_side_effects [#title] => Side Effects [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Side Effects: 

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

[#printed] => 1 ) [field_storage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_storage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 11 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_storage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

) [#title] => [#description] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_storage [#title] => Storage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Storage: 

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [field_packing] => Array ( [#type_name] => product [#context] => full [#field_name] => field_packing [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 12 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_packing [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Injection 1G/10ml: 5 Ampoules/box [format] => 1 [safe] =>

• Injection 1G/10ml: 5 Ampoules/box

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Injection 1G/10ml: 5 Ampoules/box

) [#title] => [#description] => [#children] =>

• Injection 1G/10ml: 5 Ampoules/box

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Injection 1G/10ml: 5 Ampoules/box

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Packing: 

• Injection 1G/10ml: 5 Ampoules/box

[#printed] => 1 ) [field_references] => Array ( [#type_name] => product [#context] => full [#field_name] => field_references [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 13 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_references [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_references [#title] => References [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_pdf] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pdf [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 14 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pdf [#weight] => 0 [#theme] => filefield_formatter_default [#item] => Array ( [fid] => 173 [uid] => 1 [filename] => methocarbamol.pdf [filepath] => sites/default/files/pdf/methocarbamol.pdf [filemime] => application/pdf [filesize] => 144121 [status] => 1 [timestamp] => 1329486392 [list] => 1 [data] => [i18nsync] => 1 [nid] => 278 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pdf [#title] => PDF [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_related_products] => Array ( [#type_name] => product [#context] => full [#field_name] => field_related_products [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 15 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 0 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [1] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 1 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 1 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [2] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 2 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 2 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_related_products [#title] => Related Products [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
Brand Name: 

RELAXIMOL ®

Dosage Form: 

Injection 1G/10ml

Pharmacological Category: 

Central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

Therapeutic Category: 

Antimyasthenics, Muscle Relaxant

Pregnancy Category: 

C

The mechanism of action of Methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics: 

In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine.

Indications: 

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Contraindications: 

• Methocarbamol is contraindicated in patients hypersensitive to Methocarbamol or to any of the ampoule components.

Precautions: 

• Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
• Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug Interactions: 

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), other muscle relaxants, and narcotic pain relievers (such as codeine). This medication may interfere with certain laboratory tests (including VMA or 5-HIAA urine screening test), possibly causing false test results.

Side Effects: 

Cardiovascular:
Cardiovascular side effects have included syncope, hypotension, and bradycardia.

Nervous system:
Nervous system side effects have included dizziness, lightheadedness, vertigo, headache, drowsiness, fainting, and mild muscular incoordination. Convulsions have been reported with intravenous administration, especially in patients with a history of epilepsy.

Dermatologic:
Dermatologic side effects have included urticaria, pruritus, rash, sloughing, thrombophlebitis, and pain at the injection site.

Ocular:
Ocular side effects have included blurred vision, conjunctivitis, nystagmus, and diplopia.

Respiratory:
Respiratory side effects have included nasal congestion, bronchospasm, and anaphylaxis.

Gastrointestinal:
Gastrointestinal side effects have included gastrointestinal upset, anorexia, and adynamic ileus.

Other:
Other side effects have included metallic taste and fever.

Effects on lab tests have included a possible color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Hematologic:
Hematologic side effects have included hemolysis, particularly with intravenous injection.

Renal:
Larger amounts of PEG 300 can increase preexisting renal acidosis and urea retention in patients with renal insufficiency.
Renal side effects including urine discoloration (black, blue, brown, or green) have been reported after oral administration in some patients.

General:
General side effects have included angioneurotic edema.

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Injection 1G/10ml: 5 Ampoules/box

[#printed] => 1 ) [links] => Array ( [node_translation_fa] => Array ( [title] => فارسی [href] => node/105 [language] => stdClass Object ( [language] => fa [name] => Persian [native] => فارسی [direction] => 1 [enabled] => 1 [plurals] => 0 [formula] => [domain] => [prefix] => fa [weight] => 3 [javascript] => ) [attributes] => Array ( [title] => متوکاربامول [class] => translation-link ) ) ) )
button

CONTACT US:

Head Office:
Address: No.1, Beastoon Ave., Dr. Fatemi Sq., Tehran1431663135 Iran
Tel: (+98 21)-889 65323
Fax: (+98 21)-889 57056
Factory:
Address: Caspian tamin Pharmaceutical Co., Entrance 1, Rasht Industrial Zone, Rasht, Guilan, Iran
Tel: (+98 131) 338-2511- 8
Fax: (+98 131) 338 – 2517